Skip to main content
. 2017 Aug 21;1:PO.17.00059. doi: 10.1200/PO.17.00059

Fig 1.

Fig 1.

(A) Schematic for ECOG-ACRIN-5103 and (B) CONSORT diagram for ECOG-ACRIN-5103. AC, intravenous doxorubicin and cyclophosphamide; B, bevacizumab; BAC, bevacizumab concurrent with intravenous doxorubicin and cyclophosphamide; BT, bevacizumab concurrent with paclitaxel; HER2, human epidermal growth factor receptor 2; LN, lymph node; T, paclitaxel, +, positive; -, negative.